Horizon Europe Avrupa Birliği
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · Avrupa Birliği
Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies…
Full title in the source: Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
10 Şubat 2027 tarihinde açılıyor
AB Ufuk Avrupa programı tarafından 3 hibe bekleniyor; proje başına €8 milyon – €10 milyon; toplam bütçe €26 milyon. Başvurular 16 Eylül 2027 tarihinde kapanıyor (AB çağrıları genellikle Brüksel saatiyle 17:00’de kapanır). AB üye ülkelerindeki ve Türkiye gibi ortak ülkelerdeki kuruluşlar genellikle katılabilir; konu koşulları belirleyicidir.
- Son başvuru
- 16 Eylül 2027 (305 gün kaldı)
- Açılış
- 10 Şubat 2027
- Hibe tutarı
- Proje başına €8 milyon – €10 milyon
- Toplam bütçe
- €26 milyon
- Destek oranı
- Programa göre değişir — çağrı koşullarına bakın
- Toplam bütçe
- €26 milyon
- Beklenen hibe sayısı
- 3
- Faaliyet türü
- HORIZON Pre-commercial Procurement · HORIZON Action Grant Budget-Based
- Olası başvuru sahipleri
- Şirketler, KOBİ’ler / girişimler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma, Kamu kurumları Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
- Fon sağlayıcı
- Horizon Europe (HORIZON)
- Referans
- HORIZON-MISS-2027-02-CANCER-05
- Çağrı
- HORIZON-MISS-2027-02
- Son kontrol
- 14 Kasım 2026
Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.
Beklenen sonuçlar
This action supports the follow-up to the July 2023 Communication on EU Missions assessment [1] . Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
• Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions.
• The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models.
• Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer.
Tam metni oku
• Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment.
• Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research.
Kapsam
Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines [2] .
Proposals should address all of the following:
• The focus should be on affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines that benefit cancer patients. Within this topic, it is possible to foresee the transfer and adaptation of solutions and/or interventions from other sectors to healthcare systems. It is open both to proposals requiring improvements based on one specific solution or technology, or medical device as well as to proposals requiring end-to-end solutions that need combinations of different types of innovation.
• The requested innovative solutions for healthcare systems in the areas of affordable cancer technologies, cancer medical devices, or cancer medicines should be clinically validated, piloted or upscaled by the participating procurers in at least five different countries across the EU Member States and Associated Countries.
Tam metni oku
• Continuous dialogue between the demand and supply side is required for the success of pre-commercial procurement. Therefore the effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers/families, cancer patient representatives, local or regional medical services, hospitals, production facilities) must be considered in the proposal. To stimulate dialogue with the supply side, procurers are required to organise an open-market consultation before launching the procurement and to promote the call for tenders widely across Europe to potentially interested suppliers.
• Procurers should declare in the proposal their interest to purchase at least one solution resulting from the PCP in case the PCP delivers successful solutions and indicate whether they will (1) procure the solution(s) as part of the PCP or (2) in a separate follow-up procurement after the PCP. In the first case, procurers can implement the project as a fast-track PCP (see general annex H) and foresee the budget to purchase at least one solution during the PCP. In the second case, the procurers must include in the proposal a deliverable that prepares the follow-up procurement to purchase successful solution(s) after the PCP.
• Activities covered should support national healthcare systems and mobilise technical assistance and/or capacity building to other procurers beyond the project to mainstream PCP implementation and to remove obstacles for introducing the innovative solutions for the benefit of cancer patients to be procured into the market.
[1] EUR-Lex - 52023DC0457 - EN - EUR-Lex
[2] Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative…
Kimler başvurabilir
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.
Zamanlama
Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
Nasıl başvurulur
- Portaldaki konunun tamamını okuyun: beklenen sonuçlar, kapsam, faaliyet türü ve ülke veya konsorsiyum kısıtlamaları dahil uygunluk koşulları.
- Kuruluşunuzu AB Funding & Tenders Portalına kaydederek her ortak için bir PIC numarası alın.
- İşbirliğine dayalı araştırma ve yenilik projeleri genellikle üç farklı AB üye ülkesi veya ortak ülkeden en az üç bağımsız ortak gerektirir (Türkiye Ufuk Avrupa’ya ortak ülkedir). Bu konudaki kuralı doğrulayın.
- Bölüm A’yı (portalda doldurulan idari formlar ve bütçe) ve Bölüm B’yi (bu faaliyet türü için resmi şablondaki teknik açıklama) hazırlayın.
- Son başvuru günü kapanış saatinden önce portal üzerinden gönderin. Geç başvurular kabul edilmez.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Resmi kaynaklar
Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 14 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.
Horizon Europe: diğer çağrılar
Horizon Europe Avrupa Birliği
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe Avrupa Birliği
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe Avrupa Birliği
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe Avrupa Birliği
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…